China clears Alphamab’s HER2 bispecific antibody in gastric cancer
· tamra sami
AI Briefing
- • China's National Medical Products Administration approves Alphamab's HER2 bispecific antibody anbenitamab for gastric cancer.
- • Approval granted for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
- • Condition is for those who have received at least one trastuzumab-containing regimen previously.
Context
China's National Medical Products Administration has approved anbenitamab, a HER2 bispecific antibody developed by Suzhou Alphamab Co. Ltd. The approval is for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
The approval of anbenitamab is for patients who have received at least one trastuzumab-containing regimen, through priority review.
Advertisement